GRAIL INC (GRAL) Stock Fundamental Analysis

NASDAQ:GRAL • US3847471014

51.79 USD
+1.44 (+2.86%)
At close: Feb 25, 2026
51.49 USD
-0.3 (-0.58%)
After Hours: 2/25/2026, 7:22:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall GRAL gets a fundamental rating of 4 out of 10. We evaluated GRAL against 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GRAL as it has an excellent financial health rating, but there are worries on the profitability. GRAL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year GRAL has reported negative net income.
  • GRAL had a negative operating cash flow in the past year.
  • GRAL had negative earnings in each of the past 5 years.
  • In the past 5 years GRAL always reported negative operating cash flow.
GRAL Yearly Net Income VS EBIT VS OCF VS FCFGRAL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2021 2022 2023 2024 2025 -1B -2B -3B -4B -5B

1.2 Ratios

  • GRAL has a Return On Assets of -15.62%. This is in the better half of the industry: GRAL outperforms 79.46% of its industry peers.
  • Looking at the Return On Equity, with a value of -18.14%, GRAL belongs to the top of the industry, outperforming 84.64% of the companies in the same industry.
Industry RankSector Rank
ROA -15.62%
ROE -18.14%
ROIC N/A
ROA(3y)-39.79%
ROA(5y)-48.3%
ROE(3y)-45.67%
ROE(5y)-53.29%
ROIC(3y)N/A
ROIC(5y)N/A
GRAL Yearly ROA, ROE, ROICGRAL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • GRAL's Gross Margin of 46.88% is fine compared to the rest of the industry. GRAL outperforms 75.24% of its industry peers.
  • In the last couple of years the Gross Margin of GRAL has grown nicely.
  • The Profit Margin and Operating Margin are not available for GRAL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.56%
GM growth 5YN/A
GRAL Yearly Profit, Operating, Gross MarginsGRAL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • GRAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GRAL has more shares outstanding
  • GRAL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRAL Yearly Shares OutstandingGRAL Yearly Shares OutstandingYearly Shares Outstanding 2019 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
GRAL Yearly Total Debt VS Total AssetsGRAL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • GRAL has an Altman-Z score of -2.58. This is a bad value and indicates that GRAL is not financially healthy and even has some risk of bankruptcy.
  • GRAL has a Altman-Z score of -2.58. This is comparable to the rest of the industry: GRAL outperforms 48.37% of its industry peers.
  • There is no outstanding debt for GRAL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.58
ROIC/WACCN/A
WACC8.68%
GRAL Yearly LT Debt VS Equity VS FCFGRAL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • GRAL has a Current Ratio of 7.61. This indicates that GRAL is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of GRAL (7.61) is better than 72.94% of its industry peers.
  • A Quick Ratio of 7.61 indicates that GRAL has no problem at all paying its short term obligations.
  • GRAL's Quick ratio of 7.61 is fine compared to the rest of the industry. GRAL outperforms 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 7.61
Quick Ratio 7.61
GRAL Yearly Current Assets VS Current LiabilitesGRAL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • GRAL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.10%, which is quite impressive.
  • GRAL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.18%.
  • The Revenue has been growing by 38.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)83.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.15%
Revenue 1Y (TTM)17.18%
Revenue growth 3Y38.37%
Revenue growth 5YN/A
Sales Q2Q%13.97%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.39% on average over the next years.
  • Based on estimates for the next years, GRAL will show a very strong growth in Revenue. The Revenue will grow by 33.77% on average per year.
EPS Next Y-4.16%
EPS Next 2Y-1.36%
EPS Next 3Y1.93%
EPS Next 5Y4.39%
Revenue Next Year19.76%
Revenue Next 2Y18.66%
Revenue Next 3Y23.14%
Revenue Next 5Y33.77%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
GRAL Yearly Revenue VS EstimatesGRAL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
GRAL Yearly EPS VS EstimatesGRAL Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2032 2033 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • GRAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GRAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRAL Price Earnings VS Forward Price EarningsGRAL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRAL Per share dataGRAL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.36%
EPS Next 3Y1.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GRAL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GRAIL INC

NASDAQ:GRAL (2/25/2026, 7:22:57 PM)

After market: 51.49 -0.3 (-0.58%)

51.79

+1.44 (+2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)05-11
Inst Owners66.06%
Inst Owner Change16.74%
Ins Owners1.06%
Ins Owner Change-23.78%
Market Cap2.02B
Revenue(TTM)147.17M
Net Income(TTM)-406.24M
Analysts80
Price Target95.06 (83.55%)
Short Float %14.51%
Short Ratio6.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.02%
Min EPS beat(2)12.61%
Max EPS beat(2)31.44%
EPS beat(4)4
Avg EPS beat(4)28.15%
Min EPS beat(4)12.61%
Max EPS beat(4)42.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.5%
Min Revenue beat(2)-7.24%
Max Revenue beat(2)0.24%
Revenue beat(4)2
Avg Revenue beat(4)-2.33%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)9.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)16.67%
EPS NQ rev (1m)1.06%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)0.28%
EPS NY rev (3m)11.59%
Revenue NQ rev (1m)3.16%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)1.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.23
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 5.69
EV/EBITDA N/A
EPS(TTM)-11.17
EYN/A
EPS(NY)-11.63
Fwd EYN/A
FCF(TTM)-8.46
FCFYN/A
OCF(TTM)-8.43
OCFYN/A
SpS3.64
BVpS57.46
TBVpS9.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.62%
ROE -18.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.88%
FCFM N/A
ROA(3y)-39.79%
ROA(5y)-48.3%
ROE(3y)-45.67%
ROE(5y)-53.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.56%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.71%
Cap/Sales 0.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.61
Quick Ratio 7.61
Altman-Z -2.58
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.15%
EPS Next Y-4.16%
EPS Next 2Y-1.36%
EPS Next 3Y1.93%
EPS Next 5Y4.39%
Revenue 1Y (TTM)17.18%
Revenue growth 3Y38.37%
Revenue growth 5YN/A
Sales Q2Q%13.97%
Revenue Next Year19.76%
Revenue Next 2Y18.66%
Revenue Next 3Y23.14%
Revenue Next 5Y33.77%
EBIT growth 1Y61.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.71%
EBIT Next 3Y11.01%
EBIT Next 5Y8.4%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

GRAIL INC / GRAL FAQ

Can you provide the ChartMill fundamental rating for GRAIL INC?

ChartMill assigns a fundamental rating of 4 / 10 to GRAL.


Can you provide the valuation status for GRAIL INC?

ChartMill assigns a valuation rating of 0 / 10 to GRAIL INC (GRAL). This can be considered as Overvalued.


How profitable is GRAIL INC (GRAL) stock?

GRAIL INC (GRAL) has a profitability rating of 2 / 10.


What is the earnings growth outlook for GRAIL INC?

The Earnings per Share (EPS) of GRAIL INC (GRAL) is expected to decline by -4.16% in the next year.